Physician profile
Rajdeep Singh
NPI 1568628691
$13,471.27
in general payments reported to CMS, 2019-2025
13 companies · $343 in 2025
The $343 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,225 · 2020: $247 · 2021: $255 · 2022: $616 · 2023: $6,976 · 2024: $809 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $4,000 · Food and Beverage: $2,460 · Travel and Lodging: $1,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $4,000.00 |
| Food and Beverage | $2,459.63 |
| Travel and Lodging | $1,669.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $5,392.19 | 2023 | Fycompa |
| Sunovion Pharmaceuticals INC. | $3,040.22 | 2019 | |
| Sk Life Science, INC. | $1,673.93 | 2020-2025 | Xcopri |
| Neuropace, INC. | $1,203.88 | 2019-2024 | |
| Medtronic USA, INC. | $951.73 | 2019 | |
| Ucb, INC. | $750.11 | 2022-2025 | Fintepla, Briviact |
| Idorsia Pharmaceuticals US INC | $123.38 | 2023 | Quviviq |
| Eisai INC. | $119.51 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $109.73 | 2024 | Lumryz |
| Zimmer Biomet Holdings, INC. | $56.67 | 2019 | |
| Neurelis, INC. | $35.48 | 2024 | Valtoco |
| Ceribell, INC. | $14.44 | 2025 | Pocket Eeg Device |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajdeep Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.